The stock of Bausch Health Companies Inc (BHC) has gone up by 2.51% for the week, with a 14.80% rise in the past month and a -1.55% drop in the past quarter. The volatility ratio for the week is 4.54%, and the volatility levels for the past 30 days are 3.13% for BHC. The simple moving average for the past 20 days is 5.94% for BHC’s stock, with a -17.97% simple moving average for the past 200 days.
Is It Worth Investing in Bausch Health Companies Inc (NYSE: BHC) Right Now?
The 36-month beta value for BHC is at 0.73. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BHC is 320.73M, and currently, shorts hold a 6.23% of that float. The average trading volume for BHC on September 10, 2024 was 3.66M shares.
BHC) stock’s latest price update
Bausch Health Companies Inc (NYSE: BHC)’s stock price has gone rise by 0.36 in comparison to its previous close of 6.20, however, the company has experienced a 2.51% increase in its stock price over the last five trading days. accesswire.com reported 2024-08-13 that For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / August 13, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals (“Salix”), today announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with Piper Sandler repeating the rating for BHC by listing it as a “Underweight.” The predicted price for BHC in the upcoming period, according to Piper Sandler is $3 based on the research report published on August 02, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see BHC reach a price target of $8. The rating they have provided for BHC stocks is “Mkt Perform” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Buy” to BHC, setting the target price at $16 in the report published on September 20th of the previous year.
BHC Trading at -1.70% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.71% of loss for the given period.
Volatility was left at 3.13%, however, over the last 30 days, the volatility rate increased by 4.54%, as shares surge +14.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.98% lower at present.
During the last 5 trading sessions, BHC rose by +2.22%, which changed the moving average for the period of 200-days by -10.20% in comparison to the 20-day moving average, which settled at $5.91. In addition, Bausch Health Companies Inc saw -22.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHC starting from Carson Seana, who sale 13,370 shares at the price of $6.21 back on Sep 06 ’24. After this action, Carson Seana now owns 435,198 shares of Bausch Health Companies Inc, valued at $83,028 using the latest closing price.
Carson Seana, the Officer of Bausch Health Companies Inc, proposed sale 13,370 shares at $6.21 during a trade that took place back on Sep 06 ’24, which means that Carson Seana is holding shares at $83,028 based on the most recent closing price.
Stock Fundamentals for BHC
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.92 for the gross margin
The net margin for Bausch Health Companies Inc stands at -0.0. The total capital return value is set at 0.05.
Based on Bausch Health Companies Inc (BHC), the company’s capital structure generated 1.06 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at -18.43. The interest coverage ratio of the stock is -0.88.
Currently, EBITDA for the company is 2.89 billion with net debt to EBITDA at -19.55. When we switch over and look at the enterprise to sales, we see a ratio of 2.54. The receivables turnover for the company is 4.37for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.19.
Conclusion
In conclusion, Bausch Health Companies Inc (BHC) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
